Le navigateur que vous utilisez n’est pas pris en charge.
Il est possible que certaines fonctionnalités de ce site ne s’affichent pas correctement. Pour une expérience de navigation optimale, veuillez consulter ce site dans Chrome, Firefox, Safari ou Edge.

Congrès et publications

Documents du congrès

Accéder aux résumés, posters et présentations en anglais présentés aux congrès suivants

Décembre 2023

American Society of Hematology (Société américaine d’hématologie) (ASH)

American Society of Hematology (Société américaine d’hématologie) (ASH)

Décembre 2023 (San Diego, Californie, États-Unis)

Posters

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia who progressed in the ALPINE study Broad superiority of zanubrutinib over bendamustine + rituximab across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies

Résumés

A phase 4, observational study evaluating the efficacy and safety of the Bruton tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with Waldenström macroglobulinemia (WM) Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Genomic landscape of ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies treated with zanubrutinib in a phase 2 study Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Décembre 2023

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

Novembre 2023

European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)

European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)

Novembre 2023 (Singapour)
Novembre 2023

Australasian Gastro-Intestinal Trials Group (Groupe australasien d’essais gastro-intestinaux) (AGITG)

Novembre 2023

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

Novembre 2023 (Copenhague, Danemark)

Posters

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review

Résumés

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review
Novembre 2023

Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)


Publications les plus récentes

Image de la bannière avec molécule bleue et rouge Votre accès à ces articles peut être conditionné à vos abonnements aux journaux ou à ceux de votre institution.

Rechercher les publications et les documents des congrès

Ce site web héberge une base de données de publications et de documents de congrès issus des congrès médicaux dans le monde entier. Utilisez notre moteur de recherche ci-dessous pour accéder aux informations utiles aux besoins de votre recherche.

BeiGene, Ltd. maintient le site pour votre information et éducation personnelles et à des fins de communication. N’hésitez pas à explorer le site. Vous ne pouvez toutefois pas distribuer, modifier, transmettre, réutiliser, republier ou utiliser le contenu du site à destination du public ou à toute fin commerciale, sans l’autorisation écrite de BeiGene, ce qui inclut également le texte et les images.  
 
Il s’agit d’une ressource médicale en ligne fournie à titre d’information scientifique et clinique. BeiGene ne fait aucune déclaration qui présenterait les informations sur ce site comme appropriées pour tous les pays ou régions. Si vous choisissez d’accéder à ce site, vous devez vous conformer aux dispositions légales applicables. 

Certains contenus ne sont disponibles qu'en Anglais.

Powered by Translations.com GlobalLink OneLink Software